Adapting psychedelic medicine for headache and chronic pain disorders

References

• Treede RD, Rief W, Barke A, et al. A classification of chronic pain for ICD-11. Pain. 2015;156(6):1003–1007. doi: 10.1097/j.pain.0000000000000160
   PubMed Web of Science ®Google Scholar
• Zia FZ, Baumann MH, Belouin SJ, et al. Are psychedelic medicines the reset for chronic pain? Preliminary findings and research needs. Preliminary findings and research needs. Neuropharmacology. 2023;233:109528.
   PubMed Web of Science ®Google Scholar
• Nichols DE, Barker EL. Psychedelics. Pharmacol Rev. 2016;68(2):264–355. doi: 10.1124/pr.115.011478
   PubMed Web of Science ®Google Scholar
• Johnson M, Richards W, Griffiths R. Human hallucinogen research: guidelines for safety. J Psychopharmacol. 2008;22(6):603–620. doi: 10.1177/0269881108093587
   PubMed Web of Science ®Google Scholar
• Tai SJ, Nielson EM, Lennard-Jones M, et al. Development and Evaluation of a therapist training program for psilocybin therapy for treatment-resistant depression in clinical research. Front Psychiatry. 2021;12:586682. doi: 10.3389/fpsyt.2021.586682
   PubMed Web of Science ®Google Scholar
• Chen T, Taniguchi W, Chen QY, et al. Top-down descending facilitation of spinal sensory excitatory transmission from the anterior cingulate cortex. Nat Commun. 2018;9(1):1886. doi: 10.1038/s41467-018-04309-2
   PubMed Web of Science ®Google Scholar
• Wager TD, Atlas LY, Lindquist MA, et al. An fMRI-based neurologic signature of physical pain. N Engl J Med. 2013;368(15):1388–1397. doi: 10.1056/NEJMoa1204471
   PubMed Web of Science ®Google Scholar
• Bushnell MC, Ceko M, Low LA. Cognitive and emotional control of pain and its disruption in chronic pain. Nat Rev Neurosci. 2013;14(7):502–511. doi: 10.1038/nrn3516
   PubMed Web of Science ®Google Scholar
• Moayedi M, Davis KD. Theories of pain: from specificity to gate control. J Neurophysiol. 2013;109(1):5–12. doi: 10.1152/jn.00457.2012
   PubMed Web of Science ®Google Scholar
• Fenton BW, Shih E, Zolton J. The neurobiology of pain perception in normal and persistent pain. Pain Manag. 2015;5(4):297–317. doi: 10.2217/pmt.15.27
   PubMedGoogle Scholar
• Raja SN, Carr DB, Cohen M, et al. The revised international association for the study of pain definition of pain: concepts, challenges, and compromises. Pain. 2020;161(9):1976–1982. doi: 10.1097/j.pain.0000000000001939
   PubMed Web of Science ®Google Scholar
• Greenspan JD, Craft RM, LeResche L, et al. Studying sex and gender differences in pain and analgesia: a consensus report. Pain. 2007;132(Suppl 1):S26–S45. doi: 10.1016/j.pain.2007.10.014
   PubMed Web of Science ®Google Scholar
• Fallon M, Giusti R, Aielli F, et al. Management of cancer pain in adult patients: ESMO clinical practice guidelines. Ann Oncol. 2018;29:iv166–iv91. doi: 10.1093/annonc/mdy152
   PubMed Web of Science ®Google Scholar
• Urits I, Burshtein A, Sharma M, et al. Low back pain, a Comprehensive review: Pathophysiology, diagnosis, and treatment. Curr Pain Headache Rep. 2019;23(3):23. doi: 10.1007/s11916-019-0757-1
   PubMed Web of Science ®Google Scholar
• Bigal ME, Lipton RB. Migraine chronification. Curr Neurol Neurosci Rep. 2011;11(2):139–148. doi: 10.1007/s11910-010-0175-6
   PubMed Web of Science ®Google Scholar
• Lee M, Silverman SM, Hansen H, et al. A comprehensive review of opioid-induced hyperalgesia. Pain Physician. 2011;14(2;3):145–161. doi: 10.36076/ppj.2011/14/145
   PubMed Web of Science ®Google Scholar
• Magnoux E, Zlotnik G. Outpatient intravenous dihydroergotamine for refractory cluster headache. Headache. 2004;44(3):249–255. doi: 10.1111/j.1526-4610.2004.04055.x
   PubMed Web of Science ®Google Scholar
• Mather PJ, Silberstein SD, Schulman EA, et al. The treatment of cluster headache with repetitive intravenous dihydroergotamine. Headache. 1991;31(8):525–532. doi: 10.1111/j.1526-4610.1991.hed3108525.x
   PubMed Web of Science ®Google Scholar
• Nagy AJ, Gandhi S, Bhola R, et al. Intravenous dihydroergotamine for inpatient management of refractory primary headaches. Neurology. 2011;77(20):1827–1832. doi: 10.1212/WNL.0b013e3182377dbb
   PubMed Web of Science ®Google Scholar
• Schindler EA, Gottschalk CH, Weil MJ, et al. Indoleamine Hallucinogens in cluster headache: results of the Clusterbusters medication use survey. J Psychoactive Drugs. 2015;47(5):372–381. doi: 10.1080/02791072.2015.1107664
   PubMed Web of Science ®Google Scholar
• Bailey J, Kempner J. Standards without Labs: drug development in the psychedelic underground. Citiz Sci Theory Pract. 2022;7(1):41. doi: 10.5334/cstp.527
   Google Scholar
• Sewell RA, Halpern JH, Pope HG Jr. Response of cluster headache to psilocybin and LSD. Neurology. 2006;66(12):1920–1922. doi: 10.1212/01.wnl.0000219761.05466.43
   PubMed Web of Science ®Google Scholar
• Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211. doi: 10.1177/0333102417738202
   PubMed Web of Science ®Google Scholar
• Burch R. Migraine and tension-type headache: Diagnosis and treatment. Med Clin North Am. 2019;103(2):215–233. doi: 10.1016/j.mcna.2018.10.003
   PubMed Web of Science ®Google Scholar
• Akerman S, Holland PR, Goadsby PJ. Diencephalic and brainstem mechanisms in migraine. Nat Rev Neurosci. 2011;12(10):570–584. doi: 10.1038/nrn3057
   PubMed Web of Science ®Google Scholar
• Andersson M, Persson M, Kjellgren A. Psychoactive substances as a last resort—a qualitative study of self-treatment of migraine and cluster headaches. Harm Reduct J. 2017;14(1):60. doi: 10.1186/s12954-017-0186-6
   PubMedGoogle Scholar
• Takahashi TT, Ornello R, Quatrosi G, et al. Medication overuse and drug addiction: a narrative review from addiction perspective. J Headache Pain. 2021;22(1):32. doi: 10.1186/s10194-021-01224-8
   PubMed Web of Science ®Google Scholar
• Rueda Vega M, Martinez-Fernandez A, Quintas S, et al. “The Triptan’s Hangover”: A multicentric cross-sectional Observational study of the adverse events of triptans in patients with migraine. Clin Neuropharmacol. 2022;45(2):21–26. doi: 10.1097/WNF.0000000000000498
   PubMed Web of Science ®Google Scholar
• Rapoport AM. What happens to the old headache medicines? Headache. 2012;52(4):701–706. doi: 10.1111/j.1526-4610.2012.02123.x
   PubMed Web of Science ®Google Scholar
• Burish MJ, Pearson SM, Shapiro RE, et al. Cluster headache is one of the most intensely painful human conditions: results from the International cluster headache questionnaire. Headache. 2021;61(1):117–124. doi: 10.1111/head.14021
   PubMed Web of Science ®Google Scholar
• Schindler EAD, Sewell RA, Gottschalk CH, et al. Exploratory investigation of a patient-informed low-dose psilocybin pulse regimen in the suppression of cluster headache: results from a randomized, double-blind, placebo-controlled trial. Headache. 2022;62(10):1383–1394. doi: 10.1111/head.14420
   PubMed Web of Science ®Google Scholar
• Madsen MK, Petersen AS, Stenbæk DS, et al. Psilocybin-induced reduction in chronic cluster headache attack frequency correlates with changes in hypothalamic functional connectivity. medRxiv Preprint. 2022. https://www.medrxiv.org/content/10.1101/2022.07.10.22277414v1
   Google Scholar
• Karst M, Halpern JH, Bernateck M, et al. The non-hallucinogen 2-bromo-lysergic acid diethylamide as preventative treatment for cluster headache: an open, non-randomized case series. Cephalalgia. 2010;30(9):1140–1144. doi: 10.1177/0333102410363490
   PubMed Web of Science ®Google Scholar
• Di Lorenzo C, Coppola G, Di Lorenzo G, et al. The use of illicit drugs as self-medication in the treatment of cluster headache: results from an Italian online survey. Cephalalgia. 2016;36(2):194–198. doi: 10.1177/0333102415583145
   PubMed Web of Science ®Google Scholar
• de Coo IF, Naber WC, Wilbrink LA, et al. Increased use of illicit drugs in a Dutch cluster headache population. Cephalalgia. 2019;39:626–634. doi: 10.1177/0333102418804160
   PubMed Web of Science ®Google Scholar
• Sicuteri F. Prophylactic treatment of migraine by Means of lysergic acid Derivatives. Triangle; The Sandoz Journal Of Medical Science. 1963;6:116–125.
   PubMedGoogle Scholar
• Schindler EAD, Sewell RA, Gottschalk CH, et al. Exploratory controlled study of the migraine-Suppressing effects of psilocybin. Neurotherapeutics. 2021;18(1):534–543. doi: 10.1007/s13311-020-00962-y
   PubMed Web of Science ®Google Scholar
• GBD Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global burden of disease study 2016. Lancet. 2017;390:1211–1259.
   PubMed Web of Science ®Google Scholar
• Dodick DW, Goadsby PJ, Lucas C, et al. Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: results from 3-month double-blind treatment. Cephalalgia. 2020;40(9):935–948. doi: 10.1177/0333102420905321
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Dodick DW, Leone M, et al. Trial of galcanezumab in prevention of episodic cluster headache. N Engl J Med. 2019;381(2):132–141. doi: 10.1056/NEJMoa1813440
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Reuter U, Hallstrom Y, et al. A controlled trial of Erenumab for episodic migraine. N Engl J Med. 2017;377(22):2123–2132. doi: 10.1056/NEJMoa1705848
   PubMed Web of Science ®Google Scholar
• Thorn BE, Pence LB, Ward LC, et al. A randomized clinical trial of targeted cognitive behavioral treatment to reduce catastrophizing in chronic headache sufferers. J Pain. 2007;8(12):938–949. doi: 10.1016/j.jpain.2007.06.010
   PubMed Web of Science ®Google Scholar
• Ljubisavljevic M, Ignjatovic A, Ljubisavljevic S. The ruminative thought style with associated anxiety influences the occurrence of medication-overuse headache. J Clin Neurol. 2021;17(3):419–427. doi: 10.3988/jcn.2021.17.3.419
   PubMed Web of Science ®Google Scholar
• Drahovzal DN, Stewart SH, Sullivan MJ. Tendency to catastrophize somatic sensations: pain catastrophizing and anxiety sensitivity in predicting headache. Cogn Behav Ther. 2006;35(4):226–235. doi: 10.1080/16506070600898397
   PubMedGoogle Scholar
• Schindler EAD, Wallace RM, Sloshower JA, et al. Neuroendocrine associations underlying the Persistent therapeutic effects of classic Serotonergic psychedelics. Front Pharmacol. 2018;9:177. doi: 10.3389/fphar.2018.00177
   PubMed Web of Science ®Google Scholar
• Carhart-Harris RL, Erritzoe D, Williams T, et al. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. In: Proceedings of the National Academy of Sciences of the United States of America; 2012;109:p. 2138–2143.
   Google Scholar
• Shein HM, Wilson S, Larin F, et al. Stimulation of(14C)serotonin synthesis from (14C)tryptophan by mescaline in rat pineal organ cultures. Life Sci. 1971;II(10):273–282. doi: 10.1016/0024-3205(71)90066-X
   Google Scholar
• Steardo L, Monteleone P, Trabace L, et al. Serotonergic modulation of rat pineal gland activity: in vivo evidence for a 5-Hydroxytryptamine(2C) receptor involvement. J Pharmacol Exp Ther. 2000;295:266–273.
   PubMed Web of Science ®Google Scholar
• Leone M, D’Amico D, Moschiano F, et al. Melatonin versus placebo in the prophylaxis of cluster headache: a double-blind pilot study with parallel groups. Cephalalgia. 1996;16(7):494–496. doi: 10.1046/j.1468-2982.1996.1607494.x
   PubMed Web of Science ®Google Scholar
• Pergolizzi JV Jr., Magnusson P, LeQuang JA, et al. Exploring the Connection between sleep and cluster headache: a narrative review. Pain Ther. 2020;9(2):359–371. doi: 10.1007/s40122-020-00172-6
   PubMed Web of Science ®Google Scholar
• Kast E. Attenuation of anticipation: a therapeutic use of lysergic acid diethylamide. Psychiatr Q. 1967;41(4):646–657. doi: 10.1007/BF01575629
   PubMed Web of Science ®Google Scholar
• Depoortere H, Loew DM. Alterations in sleep-wakefulness cycle in rats following treatment with (+)-lysergic acid diethylamide (LSD-25). Br J Pharmacol. 1971;41:402P–403P.
   PubMed Web of Science ®Google Scholar
• Depoortere H, Loew DM. Proceedings: Alterations in the sleep-wakefulness cycle in rats after administration of (-)-LSD or BOL-148: a comparison with (+)-LSD. Br J Pharmacol. 1972;44:354P–355P.
   PubMed Web of Science ®Google Scholar
• Kay DC, Martin WR. LSD and tryptamine effects on sleep/wakefulness and electrocorticogram patterns in intact cats. Psychopharmacology. 1978;58(3):223–228. doi: 10.1007/BF00427383
   PubMed Web of Science ®Google Scholar
• May A, Goadsby PJ. Hypothalamic involvement and activation in cluster headache. Current Science Inc. 2001;5(1):60–66. doi: 10.1007/s11916-001-0011-4
   Google Scholar
• May A. Cluster headache: pathogenesis, diagnosis, and management. Lancet. 2005;366(9488):843–855. doi: 10.1016/S0140-6736(05)67217-0
   PubMed Web of Science ®Google Scholar
• Post MD. Treatment of cluster headache symptoms using synthetic tryptamine N,N-diallyl-5 methoxytryptamine. 2014. doi: 10.6084/M9.FIGSHARE.1119697.V1
   Google Scholar
• Davis AK, Barrett FS, May DG, et al. Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry. 2021;78(5):481–489. doi: 10.1001/jamapsychiatry.2020.3285
   PubMed Web of Science ®Google Scholar
• Bogenschutz MP, Ross S, Bhatt S, et al. Percentage of Heavy Drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with Alcohol use disorder: a randomized clinical trial. JAMA Psychiatry. 2022;79(10):953–962. doi: 10.1001/jamapsychiatry.2022.2096
   PubMed Web of Science ®Google Scholar
• Treede RD, Rief W, Barke A, et al. Chronic pain as a symptom or a disease: the IASP classification of chronic pain for the international classification of diseases (ICD-11). Pain. 2019;160(1):19–27. doi: 10.1097/j.pain.0000000000001384
   PubMed Web of Science ®Google Scholar
• Aman MM, Mahmoud A, Deer T, et al. The American Society of pain and Neuroscience (ASPN) best practices and Guidelines for the interventional management of cancer-associated pain. J Pain Res. 2021;14:2139–2164. doi: 10.2147/JPR.S315585
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Anderson BT, Andrews N, et al. If the Doors of perception were Cleansed, would chronic pain be Relieved? Evaluating the Benefits and risks of psychedelics. J Pain. 2022;23(10):1666–1679. doi: 10.1016/j.jpain.2022.05.003
   PubMed Web of Science ®Google Scholar
• Pahnke WN, Kurland AA, Goodman LE, et al. LSD-assisted psychotherapy with terminal cancer patients. Curr Psychiatr Ther. 1969;9:144–152.
   PubMedGoogle Scholar
• Kurland AA. LSD in the supportive care of the terminally ill cancer patient. J Psychoactive Drugs. 1985;17(4):279–290. doi: 10.1080/02791072.1985.10524332
   PubMed Web of Science ®Google Scholar
• Grof S, Goodman LE, Richards WA, et al. LSD-assisted psychotherapy in patients with terminal cancer. Int Pharmacopsychiatry. 1973;8(3):129–144. doi: 10.1159/000467984
   PubMedGoogle Scholar
• Ramachandran V, Chunharas C, Marcus Z, et al. Relief from intractable phantom pain by combining psilocybin and mirror visual-feedback (MVF). Neurocase. 2018;24(2):105–110. doi: 10.1080/13554794.2018.1468469
   PubMed Web of Science ®Google Scholar
• Foell J, Bekrater-Bodmann R, Diers M, et al. Mirror therapy for phantom limb pain: brain changes and the role of body representation. Eur J Pain. 2014;18(5):729–739. doi: 10.1002/j.1532-2149.2013.00433.x
   PubMed Web of Science ®Google Scholar
• Lyes M, Yang KH, Castellanos J, et al. Microdosing psilocybin for chronic pain: a case series. Pain. 2022;164(4):698–702. doi: 10.1097/j.pain.0000000000002778
   PubMed Web of Science ®Google Scholar
• Fanciullacci M, Bene ED, Franchi G, et al. Brief report: phantom limb pain: sub-hallucinogenic treatment with lysergic acid diethylamide (LSD-25). Headache. 1977;17(3):118–119. doi: 10.1111/j.1526-4610.1977.hed1703118.x
   PubMed Web of Science ®Google Scholar
• Livne O, Shmulewitz D, Walsh C, et al. Adolescent and adult time trends in US hallucinogen use, 2002–19: any use, and use of ecstasy, LSD and PCP. Addiction. 2022;117(12):3099–3109. doi: 10.1111/add.15987
   PubMed Web of Science ®Google Scholar
• Marks M. The varieties of psychedelic law. Neuropharmacology. 2023;226:109399. doi: 10.1016/j.neuropharm.2022.109399
   PubMedGoogle Scholar
• Muthukumaraswamy SD, Forsyth A, Lumley T. Blinding and expectancy confounds in psychedelic randomized controlled trials. Expert Rev Clin Pharmacol. 2021;14(9):1133–1152. doi: 10.1080/17512433.2021.1933434
   PubMed Web of Science ®Google Scholar
• Breeksema JJ, Kuin BW, Kamphuis J, et al. Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review. J Psychopharmacol. 2022;36(10):1100–1117. doi: 10.1177/02698811221116926
   PubMed Web of Science ®Google Scholar
• Simonsson O, Hendricks PS, Chambers R, et al. Prevalence and associations of challenging, difficult or distressing experiences using classic psychedelics. J Affect Disord. 2023;326:105–110. doi: 10.1016/j.jad.2023.01.073
   PubMed Web of Science ®Google Scholar
• Anderson BT, Danforth AL, Grob CS. Psychedelic medicine: safety and ethical concerns. Lancet Psychiatry. 2020;7(10):829–830. doi: 10.1016/S2215-0366(20)30146-2
   PubMed Web of Science ®Google Scholar
• Ly C, Greb AC, Cameron LP, et al. Psychedelics Promote Structural and functional Neural Plasticity. Cell Rep. 2018;23(11):3170–3182. doi: 10.1016/j.celrep.2018.05.022
   PubMed Web of Science ®Google Scholar
• Raval NR, Johansen A, Donovan LL, et al. A single dose of psilocybin Increases synaptic density and decreases 5-HT2A receptor density in the Pig brain. Int J Mol Sci. 2021;22(2):22. doi: 10.3390/ijms22020835
   Web of Science ®Google Scholar
• Dourron HM, Strauss C, Hendricks PS, et al. Self-Entropic Broadening Theory: Toward a New understanding of self and Behavior Change informed by psychedelics and psychosis. Pharmacol Rev. 2022;74(4):982–1027. doi: 10.1124/pharmrev.121.000514
   PubMed Web of Science ®Google Scholar
• Flanagan TW, Nichols CD. Psychedelics as anti-inflammatory agents. Int Rev Psychiatry. 2018;30(4):363–375. doi: 10.1080/09540261.2018.1481827
   PubMed Web of Science ®Google Scholar
• Zhao-Fleming H, Hand A, Zhang K, et al. Effect of non-steroidal anti-inflammatory drugs on post-surgical complications against the backdrop of the opioid crisis. Burns Rauma. 2018;6:25. doi: 10.1186/s41038-018-0128-x
   PubMed Web of Science ®Google Scholar
• Kawashima M, Kawanishi N, Tominaga T, et al. Icing after eccentric contraction-induced muscle damage perturbs the disappearance of necrotic muscle fibers and phenotypic dynamics of macrophages in mice. J Appl Physiol (1985). 2021;130(5):1410–1420. doi: 10.1152/japplphysiol.01069.2020
   PubMed Web of Science ®Google Scholar
• Parisien M, Lima LV, Dagostino C, et al. Acute inflammatory response via neutrophil activation protects against the development of chronic pain. Sci Transl Med. 2022;14(644):eabj9954. doi: 10.1126/scitranslmed.abj9954
   PubMed Web of Science ®Google Scholar
• Hendricks PS, Copes H, Family N, et al. Perceptions of safety, subjective effects, and beliefs about the clinical utility of lysergic acid diethylamide in healthy participants within a novel intervention paradigm: Qualitative results from a proof-of-concept study. J Psychopharmacol. 2022;36(3):337–347. doi: 10.1177/02698811211055855
   PubMed Web of Science ®Google Scholar
• Ortiz CE, Dourron HM, Sweat NW, et al. Special considerations for evaluating psilocybin-facilitated psychotherapy in vulnerable populations. Neuropharmacology. 2022;214:109127. doi: 10.1016/j.neuropharm.2022.109127
   PubMed Web of Science ®Google Scholar
• Wilkinson ST, Howard DH, Busch SH. Psychiatric practice patterns and barriers to the adoption of esketamine. JAMA. 2019;322(11):1039–1040. doi: 10.1001/jama.2019.10728
   PubMed Web of Science ®Google Scholar
• Hendricks PS. Awe: a putative mechanism underlying the effects of classic psychedelic-assisted psychotherapy. Int Rev Psychiatry. 2018;30(4):331–342. doi: 10.1080/09540261.2018.1474185
   PubMed Web of Science ®Google Scholar
• Aday JS, Davis AK, Mitzkovitz CM, et al. Predicting Reactions to psychedelic drugs: a systematic review of States and Traits related to acute drug effects. ACS Pharmacol Transl Sci. 2021;4(2):424–435. doi: 10.1021/acsptsci.1c00014
   PubMedGoogle Scholar
• Murphy R, Kettner H, Zeifman R, et al. Therapeutic alliance and rapport modulate responses to psilocybin assisted therapy for depression. Front Pharmacol. 2021;12:788155. doi: 10.3389/fphar.2021.788155
   PubMed Web of Science ®Google Scholar
• Studerus E, Gamma A, Kometer M, et al. Prediction of psilocybin response in healthy volunteers. PLoS One. 2012;7(2):e30800. doi: 10.1371/journal.pone.0030800
   PubMed Web of Science ®Google Scholar
• Sellers EM, Romach MK. Psychedelics: Science sabotaged by Social media. Neuropharmacology. 2023;227:109426. doi: 10.1016/j.neuropharm.2023.109426
   PubMed Web of Science ®Google Scholar
• Aday JS, Heifets BD, Pratscher SD, et al. Great expectations: recommendations for improving the methodological rigor of psychedelic clinical trials. Psychopharmacology. 2022;239(6):1989–2010. doi: 10.1007/s00213-022-06123-7
   PubMed Web of Science ®Google Scholar
• Johnson MW, Sewell RA, Griffiths RR. Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers. Drug Alcohol Dependence. 2012;123(1–3):132–140. doi: 10.1016/j.drugalcdep.2011.10.029
   PubMed Web of Science ®Google Scholar
• Kaptchuk TJ. The placebo effect in alternative medicine: can the performance of a healing ritual have clinical significance? Ann Intern Med. 2002;136(11):817–825. doi: 10.7326/0003-4819-136-11-200206040-00011
   PubMed Web of Science ®Google Scholar
• Barrett FS, Preller KH, Kaelen M. Psychedelics and music: neuroscience and therapeutic implications. Int Rev Psychiatry. 2018;30(4):350–362. doi: 10.1080/09540261.2018.1484342
   PubMed Web of Science ®Google Scholar
• Strickland JC, Garcia-Romeu A, Johnson MW. Set and setting: A randomized study of different Musical Genres in Supporting psychedelic therapy. ACS Pharmacol Transl Sci. 2021;4(2):472–478. doi: 10.1021/acsptsci.0c00187
   PubMedGoogle Scholar
• Matharu MS, van Vliet JA, Ferrari MD, et al. Verapamil induced gingival enlargement in cluster headache. J Neurol Neurosurg Psychiatry. 2005;76(1):124–127. doi: 10.1136/jnnp.2003.024240
   PubMed Web of Science ®Google Scholar
• Johnson S, Black QC. Can psychedelics Alleviate symptoms of cluster headache and Accompanying mental health Problems? A case report involving Hawaiian baby woodrose. J Psychoactive Drugs. 2020;2020(4):1–5. doi: 10.1080/02791072.2020.1762023
   Google Scholar
• Notice to stakeholders: health Canada’s expectations regarding risk-management measures for clinical trials involving psychedelic-assisted psychotherapy. 2022.
   Google Scholar
• Psychedelic drugs: considerations for clinical investigations guidance for Industry (Draft guidance). United States Food and Drug Administration; 2023:https://www.fda.gov/regulatory-information/search-fda-guidance-documents/psychedelic-drugs-considerations-clinical-investigations.
   Google Scholar
• Kast EC, Collins VJ. Study of lysergic acid diethylamide as an Analgesic Agent. Anesth Analg. 1964;43(3):285–291. doi: 10.1213/00000539-196405000-00013
   PubMed Web of Science ®Google Scholar
• Schindler EAD. Psychedelics as preventive treatment in headache and chronic pain disorders. Neuropharmacology. 2022;215:109166. doi: 10.1016/j.neuropharm.2022.109166
   PubMed Web of Science ®Google Scholar